San Francisco clinical-stage, AI-driven drug-design company founded in 2021 (Y Combinator-backed) that mines tens of thousands of psychoactive experience reports plus biochemical data to map receptor combinations to specific emotional and cognitive states. Its lead candidate MSD-001 is designed to produce more predictable psychedelic experiences; it had raised over $24M by mid-2025.